DurAct

bromfenac

An analgesic NSAID used for acute pain management, which was withdrawn from the market following multiple reports of liver failure.

DurAct®

Bromfenac Pain medicine A prescription NSAID-analgesic similar in efficacy to ibuprofen that was 'pulled' from the market by its producer, Wyeth-Ayerst, when it was linked to fulminant liver failure, death or need for liver transplantation
References in periodicals archive ?
(fenfluramine), Posicor (mibefradil), and Duract (bromfenac) in 1997,
Therefore using standard contact and noncontact sensors such as accelerometers, capacitive sensors, and laser based vibration sensors (velocity or displacement), the embedded or surface bonded PZT patches and piezoelectric composites (MFC, Duract) can be correlated to output engineering data for health and load monitoring applications.
Wyeth-Ayerst Laboratories, (70) for example, involved a nationwide class action against Wyeth, the manufacturer of Duract, a non-steroidal anti-inflammatory drug.
Ten of them have been withdrawn from the market since Michigan's FDA shield law went into effect, including the diabetes drug Rezulin; the heartburn drug Propulsid; the painkiller Duract; and the anti-cholesterol drug Baycol.
The nonsteroidal inflammatory drug Duract, a Wyeth-Ayerst product, which was also known to cause liver damage, was approved although 19 similar drugs were already on the market.
These include a pain killer (Duract); diet pills (Phen Fen and Redux); and a blood pressure medication (Posicor).
For example, Duract, an effective short-term painkiller, proved dangerous when prescribed beyond 10 days, which doctors routinely did.
Wolfe: Raw milk, aspirin and Reye's Syndrome, tampons and toxic shock, Phenformin and lactic acidosis, Posicor and Duract are all instances where there was clear, unequivocal data at the FDA showing harm, but where the FDA failed to either ban a product or require necessary labeling.
Drugs withdrawn between September 1997 and June of last year were Redux, Pondimin and Duract, all marketed by American Home Products Corp.; Seldane, from Hoechst AG; and Posicor, marketed by Roche AG.
The withdrawals included the obesity drug Redux, the analgesic Duract, and the cardiac drug Posicor, which were withdrawn from the market for safety reasons within a year of approval.
Matrixx Initiatives' Duract cough suppressant tablets qualifies as a demand brand in the category, in part because it offers long-lasting relief and in part because of its unique form for a cough product.
The eight drugs lately withdrawn were GlaxoSmithKline's Lotronex, for irritable bowel syndrome; American Home Products' Redux, a diet aid; the Bayer Corporation's Raxar, an antibiotic; Pfizer's Trovan, also an antibiotic; Roche's Posicor, a blood-pressure medication; Wyeth-Ayerst's Duract, a painkiller; Warner-Lambert's Rezulin, a diabetes drug; and, this spring, Organon's Raplon, an anesthetic.